Skip to content
10-Q

Quarterly Report

Panbela Therapeutics, Inc.

0001437749-24-017064

← back to feed
Filed
May 15, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 13, 2024 4.85M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$9.39M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$9.75M
Long Term Debt Q1 2024 · Mar 31, 2024 $3.19M
Long Term Debt Q1 2024 · Dec 31, 2023 $4.19M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $262K
Cash And Equivalents Q1 2024 · Dec 31, 2023 $2.58M
Stockholders Equity Q1 2024 · Mar 31, 2024 −$3.19M
Stockholders Equity Q1 2024 · Dec 31, 2023 −$4.71M
Stockholders Equity Q1 2024 · Mar 31, 2023 $2.54M
Stockholders Equity Q1 2024 · Dec 31, 2022 −$8.05M
Current Liabilities Q1 2024 · Mar 31, 2024 $10.52M
Current Liabilities Q1 2024 · Dec 31, 2023 $12.32M
Total Liabilities Q1 2024 · Mar 31, 2024 $13.71M
Total Liabilities Q1 2024 · Dec 31, 2023 $16.51M
Current Assets Q1 2024 · Mar 31, 2024 $1.79M
Current Assets Q1 2024 · Dec 31, 2023 $3.06M
Total Assets Q1 2024 · Mar 31, 2024 $10.53M
Total Assets Q1 2024 · Dec 31, 2023 $11.8M
Eps Basic Q1 2024 · Mar 31, 2024 −$2.28
Eps Basic restated Q1 2024 · Mar 31, 2023 −$392.76
Sga Expense Q1 2024 · Mar 31, 2024 $1.2M
Sga Expense Q1 2024 · Mar 31, 2023 $1.35M
Rd Expense Q1 2024 · Mar 31, 2024 $5.52M
Rd Expense Q1 2024 · Mar 31, 2023 $3.51M
Net Income Q1 2024 · Mar 31, 2024 −$7.12M
Net Income Q1 2024 · Mar 31, 2023 −$5.11M
Operating Income Q1 2024 · Mar 31, 2024 −$6.73M
Operating Income Q1 2024 · Mar 31, 2023 −$4.86M